Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma
Source: Cancer Network, April 2025
The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.
Superior efficacy was noted with nurulimab plus prolgolimab vs prolgolimab alone as first-line treatment for patients with unresectable or metastatic melanoma, according to results from the phase 3 OCTAVA trial (NCT05732805) presented at the 2025 American Association for Clinical Research Annual Meeting.
The median progression-free survival in the nurulimab plus prolgolimab group via RECIST v1.1 was 6.6 months (95% CI, 3.9-11.5), and the immune-related RECIST (iRECSIT) median PFS was 15.4 months (95% CI, 8.4-not available) compared with the prolgolimab monotherapy arm of 2.8 months (95% CI, 1.6-4.6) vs 7.4 months (95% CI, 4.2-14.8). The median follow-up was 15.7 months (95% CI, 12.4-17.2) in the RECIST v1.1 combination group vs 15.3 months (95% CI, 12.4-17.1) for the iRECIST group compared with the prolgolimab monotherapy group of 17.1 months (95% CI, 12.9-18.9) vs 15.8 months (95% CI, 14.9-18.9). Additionally, the 12-month PFS rate in the combination group was 40.1% vs 55.6%, and in the monotherapy group, it was 32.1% vs 45.9% for RECIST v1.1 and iRECIST.